Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses

Stephen D White, Laura K. Maxwell, Nancy J. Szabo, Jocelyn L. Hawkins, Cynthia Kollias-Baker

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective - To determine pharmacokinetics of azathioprine (AZA) and clinical, hematologic, and serologic effects of IV and oral administration of AZA in horses. Animals - 6 horses. Procedure - In study phase 1, a single dose of AZA was administered IV (1.5 mg/kg) or orally (3.0 mg/kg) to 6 horses, with at least 1 week between treatments. Blood samples were collected for AZA and 6-mercaptopurine (6-MP) analysis 1 hour before and at predetermined time points up to 4 hours after AZA administration. In study phase 2, AZA was administered orally (3 mg/kg) every 24 hours for 30 days and then every 48 hours for 30 days. Throughout study phase 2, blood samples were collected for CBC determination and serum biochemical analysis. Results - Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following IV administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes. Oral bioavailability of AZA was low, ranging from 1% to 7%. No horses had abnormalities on CBC determination or serum biochemical analysis, other than 1 horse that was lymphopenic on day 5 and 26 of daily treatment. This horse developed facial alopecia from which 1 colony of a Trichophyton sp was cultured; alopecia resolved within 1 month after the study ended. Conclusions and clinical relevance - Overall, no adverse effects were observed with long-term oral administration of AZA to horses, although 1 horse did have possible evidence of immunosuppression with chronic treatment. Further investigation of the clinical efficacy of AZA in the treatment of autoimmune diseases in horses is warranted.

Original languageEnglish (US)
Pages (from-to)1578-1583
Number of pages6
JournalAmerican Journal of Veterinary Research
Volume66
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Azathioprine
intravenous injection
Intravenous Administration
oral administration
pharmacokinetics
Horses
Oral Administration
Pharmacokinetics
horses
dosage
alopecia
6-Mercaptopurine
blood serum
Alopecia
Trichophyton
autoimmune diseases
immunosuppression
blood
half life
bioavailability

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. / White, Stephen D; Maxwell, Laura K.; Szabo, Nancy J.; Hawkins, Jocelyn L.; Kollias-Baker, Cynthia.

In: American Journal of Veterinary Research, Vol. 66, No. 9, 09.2005, p. 1578-1583.

Research output: Contribution to journalArticle

@article{4559b63b3bf0402082f76b18cde95d2b,
title = "Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses",
abstract = "Objective - To determine pharmacokinetics of azathioprine (AZA) and clinical, hematologic, and serologic effects of IV and oral administration of AZA in horses. Animals - 6 horses. Procedure - In study phase 1, a single dose of AZA was administered IV (1.5 mg/kg) or orally (3.0 mg/kg) to 6 horses, with at least 1 week between treatments. Blood samples were collected for AZA and 6-mercaptopurine (6-MP) analysis 1 hour before and at predetermined time points up to 4 hours after AZA administration. In study phase 2, AZA was administered orally (3 mg/kg) every 24 hours for 30 days and then every 48 hours for 30 days. Throughout study phase 2, blood samples were collected for CBC determination and serum biochemical analysis. Results - Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following IV administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes. Oral bioavailability of AZA was low, ranging from 1{\%} to 7{\%}. No horses had abnormalities on CBC determination or serum biochemical analysis, other than 1 horse that was lymphopenic on day 5 and 26 of daily treatment. This horse developed facial alopecia from which 1 colony of a Trichophyton sp was cultured; alopecia resolved within 1 month after the study ended. Conclusions and clinical relevance - Overall, no adverse effects were observed with long-term oral administration of AZA to horses, although 1 horse did have possible evidence of immunosuppression with chronic treatment. Further investigation of the clinical efficacy of AZA in the treatment of autoimmune diseases in horses is warranted.",
author = "White, {Stephen D} and Maxwell, {Laura K.} and Szabo, {Nancy J.} and Hawkins, {Jocelyn L.} and Cynthia Kollias-Baker",
year = "2005",
month = "9",
doi = "10.2460/ajvr.2005.66.1578",
language = "English (US)",
volume = "66",
pages = "1578--1583",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses

AU - White, Stephen D

AU - Maxwell, Laura K.

AU - Szabo, Nancy J.

AU - Hawkins, Jocelyn L.

AU - Kollias-Baker, Cynthia

PY - 2005/9

Y1 - 2005/9

N2 - Objective - To determine pharmacokinetics of azathioprine (AZA) and clinical, hematologic, and serologic effects of IV and oral administration of AZA in horses. Animals - 6 horses. Procedure - In study phase 1, a single dose of AZA was administered IV (1.5 mg/kg) or orally (3.0 mg/kg) to 6 horses, with at least 1 week between treatments. Blood samples were collected for AZA and 6-mercaptopurine (6-MP) analysis 1 hour before and at predetermined time points up to 4 hours after AZA administration. In study phase 2, AZA was administered orally (3 mg/kg) every 24 hours for 30 days and then every 48 hours for 30 days. Throughout study phase 2, blood samples were collected for CBC determination and serum biochemical analysis. Results - Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following IV administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes. Oral bioavailability of AZA was low, ranging from 1% to 7%. No horses had abnormalities on CBC determination or serum biochemical analysis, other than 1 horse that was lymphopenic on day 5 and 26 of daily treatment. This horse developed facial alopecia from which 1 colony of a Trichophyton sp was cultured; alopecia resolved within 1 month after the study ended. Conclusions and clinical relevance - Overall, no adverse effects were observed with long-term oral administration of AZA to horses, although 1 horse did have possible evidence of immunosuppression with chronic treatment. Further investigation of the clinical efficacy of AZA in the treatment of autoimmune diseases in horses is warranted.

AB - Objective - To determine pharmacokinetics of azathioprine (AZA) and clinical, hematologic, and serologic effects of IV and oral administration of AZA in horses. Animals - 6 horses. Procedure - In study phase 1, a single dose of AZA was administered IV (1.5 mg/kg) or orally (3.0 mg/kg) to 6 horses, with at least 1 week between treatments. Blood samples were collected for AZA and 6-mercaptopurine (6-MP) analysis 1 hour before and at predetermined time points up to 4 hours after AZA administration. In study phase 2, AZA was administered orally (3 mg/kg) every 24 hours for 30 days and then every 48 hours for 30 days. Throughout study phase 2, blood samples were collected for CBC determination and serum biochemical analysis. Results - Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following IV administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes. Oral bioavailability of AZA was low, ranging from 1% to 7%. No horses had abnormalities on CBC determination or serum biochemical analysis, other than 1 horse that was lymphopenic on day 5 and 26 of daily treatment. This horse developed facial alopecia from which 1 colony of a Trichophyton sp was cultured; alopecia resolved within 1 month after the study ended. Conclusions and clinical relevance - Overall, no adverse effects were observed with long-term oral administration of AZA to horses, although 1 horse did have possible evidence of immunosuppression with chronic treatment. Further investigation of the clinical efficacy of AZA in the treatment of autoimmune diseases in horses is warranted.

UR - http://www.scopus.com/inward/record.url?scp=27744481152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744481152&partnerID=8YFLogxK

U2 - 10.2460/ajvr.2005.66.1578

DO - 10.2460/ajvr.2005.66.1578

M3 - Article

VL - 66

SP - 1578

EP - 1583

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 9

ER -